December 20, 2016
Hisamitsu Pharmaceutical said on December 19 that it has filed a new drug application (NDA) for emedastine fumarate (HP-3060), a transdermal treatment for allergic rhinitis. Emedastine fumarate was developed into a systemic transdermal tape formulation based on the company’s proprietary...read more